Owkin signs AI drug discovery deal with Boehringer for cancer, immunology

Sept 2 — AI company Owkin said on ​Wednesday it has signed a licensing deal with Germany's Boehringer Ingelheim, giving the ‌drugmaker access to its AI research platform and patient ⁠data to speed ​up discovery of ⁠drugs for cancer and immunity-related diseases.

The ‌deal adds Boehringer ‌to a growing list of drugmakers ⁠using Owkin's AI ⁠technology, "K Pro". AstraZeneca licensed it in May, while Sanofi expanded its partnership with a five-year agreement in June.

Here are some more details:

• The deal builds on ‌the companies' pilot project ​in 2025, in which Owkin used its patient tumor samples and related biological datasets to help Boehringer prioritize potential drug targets, the AI company's CEO, Thomas Clozel, told Reuters.

• Under the new pact, ​Owkin will license multimodal oncology data ‌to Boehringer ‌and ⁠will generate new data in immunology.

• Owkin licenses, sources and generates patient data in collaboration with its global patient data network.

• ‌The companies did ​not disclose the financial ‌terms of the ⁠agreement.

(Reporting ​by Sahil Pandey in Bengaluru; Editing by Leroy ​Leo)

Related topics